The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Real-world analysis of gilteritinib for R/R FLT3-mutated AML
Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, shares some key results from a real-world analysis of gilteritinib for the treatment of relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Shimony discusses the overall survival (OS) observed in patients and the efficacy of this agent, as well as the importance of investigating other treatment combinations in the future. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
